Mucoangin Zitrone (Ambroxol Hydrochloride)

Ambroxol, the active ingredient in Mucoangin Zitrone, is a mucolytic presented as an oral formulation for oromucosal use. It reduces the viscosity of respiratory mucus and facilitates its clearance, helping to relieve cough associated with acute respiratory tract infections and is commonly used in adult patients experiencing productive cough.

GNH USA supplies Mucoangin Zitrone as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to European Union quality standards and provides regulatory documentation for global distribution.

Ambroxol is employed as a mucolytic agent to improve mucus clearance in respiratory conditions.

- Acute bronchitis: facilitates expectoration of thick sputum, reducing cough duration. - Chronic obstructive pulmonary disease (COPD) exacerbations: aids in clearing airway secretions to improve breathing. - Upper respiratory tract infection: lessens mucus viscosity, supporting symptom relief.

Ambroxol may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Taste disturbance: altered or unpleasant taste in the mouth. - Nausea: mild stomach upset. - Diarrhea: loose stools. - Skin rash: mild erythema or itching. - Headache: transient mild headache.

Serious or Rare Side Effects: - Allergic reactions: hives, swelling, or anaphylaxis. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic dysfunction: elevated liver enzymes. - Bronchospasm: worsening of breathing difficulty.

When using Ambroxol, consider the following precautions to ensure safe and effective therapy.

- Pregnancy: use only if clearly needed; limited data available. - Breastfeeding: assess risk versus benefit before use. - Renal impairment: monitor dosage in patients with reduced kidney function. - Concomitant respiratory disease: evaluate for potential bronchospasm. - Drug hypersensitivity: avoid if known allergy to Ambroxol or similar compounds. - Store at ambient temperature: keep below 25 °C, protect from moisture and direct sunlight.

Ambroxol can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Anticholinergic agents: may reduce mucociliary clearance. - Beta‑blockers: potential increase in bronchospasm risk.

Moderate Interactions (Monitor Closely): - Other mucolytics: additive effect on mucus thinning. - CYP450 inhibitors (e.g., ketoconazole): may increase Ambroxol plasma levels. - NSAIDs: possible enhanced gastrointestinal irritation. - Antihistamines: may blunt the secretolytic effect.